Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
231. |
ECCT/20/04/03 | 518 & 525-SHAN6â„¢ Study Title: Safety and Immunogenicity Study of Full Schedule (3-Dose SHAN6™) or SHAN6™- SHAN 5®- SHAN6™ Versus the Licensed Vaccine SHAN 5® With bOPV and IPV When Administered Per National Immunization Schedule in Healthy Kenyan Infants. Phase III, multi-center, randomized, active-controlled, open-label, three-arm, study in 690 infants who will receive a 3-dose primary series at 6, 10 and 14 weeks of age, of either 3-dose SHAN6™ or SHAN6™ – SHAN 5® + bOPV – SHAN6™ or SHAN 5® + bOPV – SHAN 5® + bOPV – SHAN 5® + bOPV + IPV, and a booster dose of either SHAN6™ or SHAN 5® + bOPV at 18 months of age |
Principal Investigator(s) 1. Bernhards Ogutu 2. Godfrey Allan Otieno 3. Videlis Nduba 4. Lucy Chepkurui Koech 5. samuel Gurrion Ouma 6. Janet Oyieko Site(s) in Kenya 1. Ahero Clinical Trials Unit (Kisumu county) 2. KEMRI, Centre for Respiratory Diseases Research (CRDR) (Nairobi City county) 3. KEMRI Kondele Children’s Hospital (Kisumu county) 4. KEMRI / Walter Reed Project, Clinical Research Centre, Kericho (Kericho county) 5. KEMRI CGHR, CLINICAL RESEARCH CENTRE (Kisumu county) 6. KEMRI Centre forClinical Research(CCR)_Butere County Hospital (Kakamega county) 7. CRDR_Siaya Annex(Back-up site) (Siaya county) |
11-08-2020 |
View |
232. |
ECCT/20/06/03 | CVIA078 A Phase 2b randomized, open-label, controlled, single center study in Plasmodium falciparum-infected and uninfected adults age 18-55 years old in Kenya to evaluate the efficacy of the delayed, fractional dose RTS,S/AS01E malaria vaccine in subjects treated with artemisinin combination therapy plus primaquine |
Principal Investigator(s) 1. Nathanial Kelsey Copeland Site(s) in Kenya Kombewa Clinical Research Centre |
19-08-2020 |
View |
233. |
ECCT/20/05/03 | A5381 Observational Cohort to Assess Therapeutic Efficacy and Emergence of HIV Drug Resistance Following Initiation of Tenofovir-Lamivudine-Dolutegravir (TLD) for First- or Second-Line ART or with Rifampicin-Containing TB Treatment |
Principal Investigator(s) 1. Victor Mudhune Site(s) in Kenya Kisumu Clinical Research Center |
21-08-2020 |
View |
234. |
ECCT/20/05/02 | COPCOV Chloroquine/ hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting; a randomised, placebo-controlled prophylaxis study (COPCOV) |
Principal Investigator(s) 1. Anthony Oliwa Etyang Site(s) in Kenya 1. KEMRI - Centre for Geographic Medicine Research Coast (CGMRC) (Kilifi county) 2. KEMRI-Centre for Global Health Research (CGHR) (Kisumu county) |
04-09-2020 |
View |
235. |
ECCT/20/05/01 | ChAdOx1 nCoV-19 trial A phase Ib/II single-blinded, randomised, controlled study to determine safety, immunogenicity and efficacy of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in adults in Kenya |
Principal Investigator(s) 1. George Warimwe Site(s) in Kenya KEMRI-CGMRC |
08-09-2020 |
View |
236. |
ECCT/20/06/09 | HIV-CORE 006 A Phase 1 Trial of ChAdOx1- and MVA-vectored Conserved Mosaic HIV-1 Vaccines in Healthy, Adult HIV-1-negative Volunteers in Eastern and Southern Africa |
Principal Investigator(s) 1. Professor Walter Jaoko, Jaoko, Site(s) in Kenya 1. KAVI-Institute of Clinical Research (Nairobi City county) 2. KEMRI/ Wellcome Trust Research Programme (Kilifi county) |
09-09-2020 |
View |
237. |
ECCT/20/06/04 | ANTICOV (01 COV) An open-label, multicentre, randomised, adaptive platform trial of the safety and efficacy of several therapies, including antiviral therapies, versus control in mild /moderate cases of COVID-19 |
Principal Investigator(s) 1. Bernhards Ragama Ogutu Site(s) in Kenya 1. Mbagathi Infectious Disease Hospital (Nairobi City county) 2. Kenyatta University Teaching, Referral and Research Hospital (Nairobi City county) |
18-09-2020 |
View |
238. |
ECCT/20/07/01 | Convalescent plasma trial A randomized control trial comparing convalescent plasma therapy plus standard treatment versus standard treatment alone in patients with severe COVID-19 pneumonia at a tertiary hospital |
Principal Investigator(s) 1. Dr Isaac Adembesa Kadambi Site(s) in Kenya Kenyatta University Teaching Referral and Research Hospital |
25-09-2020 |
View |
239. |
ECCT/20/06/06 | E-MOTIVE FORMATIVE Understanding effectiveness of implementation of a postpartum haemorrhage initial response bundle |
Principal Investigator(s) 1. Zahida Qureshi Site(s) in Kenya 1. Mwingi Sub county (level 4 ) hospital (Kitui county) 2. Nyeri Level 5 Hospital (Nyeri county) 3. Garissa county referral hospital (Garissa county) 4. Embu Level 5 hospital (Embu county) 5. TIGONI LEVEL 4 HOSPTIAL (Kiambu county) 6. Meru Teaching and Referral Hospital (Meru county) 7. Kitengela Sub county Hospital (Kajiado county) 8. Kakamega County Government Referral Hospital (Kakamega county) 9. Mbagathi County Hospital (Nairobi City county) 10. St. Mary\'s Mission Hospital (Nairobi City county) |
15-10-2020 |
View |
240. |
ECCT/20/06/08 | E-MOTIVE TRIAL Early detection of PPH and treatment using the WHO MOTIVE ‘first response’ bundle: a cluster randomised trial with health economic analysis and mixed-methods evaluation. |
Principal Investigator(s) 1. Zahida Qureshi Site(s) in Kenya 1. Mwingi Sub county (level 4 ) hospital (Kitui county) 2. Nyeri Level 5 Hospital (Nyeri county) 3. Garissa county referral hospital (Garissa county) 4. Embu Level 5 hospital (Embu county) 5. TIGONI LEVEL 4 HOSPTIAL (Kiambu county) 6. Meru Teaching and Referral Hospital (Meru county) 7. Kitengela Sub county Hospital (Kajiado county) 8. Kakamega County Government Referral Hospital (Kakamega county) 9. Mbagathi County Hospital (Nairobi City county) 10. St. Mary\'s Mission Hospital (Nairobi City county) |
19-10-2020 |
View |